Intestinal FXR agonism synergizes with leptin to improve obesity by reducing appetite via secretin.

Intestinal FXR agonism reduces obesity by suppressing appetite through secretin, with a significant effect observed in diet-induced and db/db mice.

• Why it matters: Obesity's link to metabolic diseases underscores the need for targeted therapies that minimize side effects; understanding mechanisms can improve treatment strategies.
• What they did: Researchers used intestinal-specific FXR agonists in mouse models, examining their effects on obesity and appetite regulation, focusing on leptin and secretin pathways.
• The result: The findings reveal that intestinal FXR activation upregulates secretin expression in a leptin-dependent manner, offering a promising approach to combat obesity by reducing appetite.